Efficacy of a Chinese herbal medicine for the treatment of atopic dermatitis: A randomised controlled study

被引:53
作者
Liu, Junfeng [1 ]
Mo, Xiumei [1 ]
Wu, Darong [2 ,3 ]
Ou, Aihua [2 ]
Xue, Suqin [1 ]
Liu, Chi [1 ]
Li, Hongyi [1 ]
Wen, Zehuai [2 ]
Chen, Dacan [1 ]
机构
[1] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Dermatol, Guangzhou, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Clin Epidemiol, Guangzhou, Guangdong, Peoples R China
[3] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
关键词
Atopic dermatitis; Randomised controlled trial; Pei Tu Qing Xin Tang; Efficacy; Traditional Chinese medicine; STAPHYLOCOCCUS-AUREUS; DOUBLE-BLIND; COLONIZATION; ECZEMA; SKIN;
D O I
10.1016/j.ctim.2015.07.006
中图分类号
R [医药、卫生];
学科分类号
100218 [急诊医学];
摘要
Background: More randomised control trials are required to assess the efficacy of traditional Chinese medicine. This multi-centre, randomised, assessor-blind, controlled study assessed the efficacy of the Chinese herbal formula Pei Tu Qing Xin Tang (PTQXT) for treating patients with atopic dermatitis (AD). Methods: Patients aged 5-25 years with moderate-to-severe AD were randomised to receive a 12-week treatment involving either oral administration of PTQXT; oral administration of PTQXT combined with an external application of Chinese herbs; or oral administration of antihistamine and a placebo of PTQXT pills added to topical I% mometasone furoate. The primary end-point measure was the change in the Scoring Atopic Dermatitis Index (SCORAD) at the end of the observation period, and secondary end-points included quality of life (QOL). The outcomes were evaluated at baseline, then every 4 weeks from week 4 to week 12 and every 8 weeks from week 12 to week 36. Results: Two hundred and seventy-five patients were recruited. During the 12-week treatment period, up to the primary end-point, the mean SCORAD decreased gradually in all three groups. At week 28 and week 36, there was a significantly greater decrease in the mean SCORAD for the Chinese herbal medicine-treated groups than for the control group (at week 28, P=0.002 and P=0.036, respectively; at week 36, P<0.001 and P=0.002, respectively). At week 36, the difference in QOL scores showed a significantly greater improvement in both Chinese herbal medicine-treated groups than in the control group (P<0.001 and P<0.001, respectively). Conclusions: PTQXT is effective in decreasing the severity of the disease and improving the QOL in patients with moderate-to-severe AD. Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-08000156. 10 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:644 / 651
页数:8
相关论文
共 34 条
[1]
[Anonymous], LIAONING J TRADIT CH
[2]
[Anonymous], 2002, COMBINATION APPL
[3]
[Anonymous], 2007, CLIN PRACTICE CHINES
[4]
[Anonymous], J N CHIN MED
[5]
[Anonymous], 2010, PHARMACOPOEIA PEOPLE
[6]
[Anonymous], CHIN J DERMATOVENERO
[7]
[Anonymous], CHIN J DERM VENEROL
[8]
[Anonymous], J LIAONING U TRADIT
[9]
[Anonymous], CHIN J DERMATOVENERO
[10]
Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review [J].
Bath-Hextall, F. J. ;
Birnie, A. J. ;
Ravenscroft, J. C. ;
Williams, H. C. .
BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (01) :12-26